{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117193","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.818437+00:00","generated_at":"2026-05-30T01:03:55.601668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia Q3 net loss $23.2M; FDA tentative approval for YUTREPIA; raised $100M","bullets":["Net loss of $23.2M ($0.30/diluted share) vs $15.8M loss a year ago; revenue $4.4M from Treprostinil injection promotion.","Cash $204.4M as of Sep 30, 2024, boosted by $67.5M public offering and $32.5M from HCRx RIFA amendment.","FDA granted tentative approval for YUTREPIA (treprostinil inhalation powder) for PAH and PH-ILD; final approval delayed until May 23, 2025.","Supreme Court rejected UTHR appeal on '793 patent; remaining '327 patent trial set for June 2025; Liquidia sued FDA over exclusivity.","Expanded Pharmosa collaboration for L606 to Europe, Japan; $3.5M upfront, up to $157.75M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117193","json":"https://secwatch.observer/filing/0001104659-24-117193.json","markdown":"https://secwatch.observer/filing/0001104659-24-117193.md","text":"https://secwatch.observer/filing/0001104659-24-117193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/0001104659-24-117193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/tm2428261d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:03:55.601668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}